Prosecution Insights
Prosecution Insights
9 pending office actions • 6 clients • 9 examiners • 8 art units • 0 of 9 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (33%) |
| §112 only | 1 (11%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 2 (22%) |
| Multi-statute (no §101) | 2 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YUNSOO | 1 | 65.8% | +34.8% |
| LEE, SIN J | 1 | 68.9% | +25.4% |
| CHANDRA, GYAN | 1 | 71.3% | +27.4% |
| NOLAN, JASON MICHAEL | 1 | 66.3% | -28.0% |
| PATEL, SAGAR S | 1 | 76.1% | +34.1% |
| D' AMBROSIO, THEA | 1 | 55.9% | +56.4% |
| SCHLOOP, ALLISON ELIZABETH | 1 | 60.0% | +59.3% |
| MIKNIS, ZACHARY J | 1 | 68.3% | +32.5% |
| REGLAS, GILLIAN CHELSEA | 1 | 29.8% | +49.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17602936 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTICS | REGLAS, GILLIAN CHELSEA | 27d |
| 18111070 | METHODS OF ANCHORING FRAGMENTED NUCLEIC ACID TARGETS IN A POLYMER MATRIX FOR IMAGING | SCHLOOP, ALLISON ELIZABETH | 71d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18011261 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | MIKNIS, ZACHARY J | 21d |
| 17602936 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTICS | REGLAS, GILLIAN CHELSEA | 27d |
| 18111070 | METHODS OF ANCHORING FRAGMENTED NUCLEIC ACID TARGETS IN A POLYMER MATRIX FOR IMAGING | SCHLOOP, ALLISON ELIZABETH | 71d |
| 19401802 | METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNS | KIM, YUNSOO | — |
| 18797689 | GAMMA-POLYGLUTAMIC ACID AND ZINC COMPOSITIONS | LEE, SIN J | — |
| 18443985 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS | CHANDRA, GYAN | — |
| 18290403 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | PATEL, SAGAR S | — |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | D' AMBROSIO, THEA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Acceleron Pharma | 3 |
| Disc Medicine | 2 |
| ArmaGen, Inc. | 1 |
| Xylonix Pte. Ltd. | 1 |
| Vizgen, Inc. | 1 |
| Encoded Therapeutics | 1 |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1613 | 1 |
| 1623 | 1 |
| 1626 | 1 |
| 1654 | 1 |
| 1683 | 1 |
| 1658 | 1 |
| 1632 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19401802 | METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNS | ArmaGen, Inc. | KIM, YUNSOO | 1641 | §103 | Final Rejection | — | Pending | Nov 26, 2025 |
| 18797689 | GAMMA-POLYGLUTAMIC ACID AND ZINC COMPOSITIONS | Xylonix Pte. Ltd. | LEE, SIN J | 1613 | §103 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18443985 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS | Acceleron Pharma, Inc. | CHANDRA, GYAN | DP | Non-Final OA | — | Pending | Feb 16, 2024 | |
| 18562510 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN | Disc Medicine, Inc. | NOLAN, JASON MICHAEL | 1623 | §102§103§112DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18290403 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | Disc Medicine, Inc. | PATEL, SAGAR S | 1626 | §103§112DPOther | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | Acceleron Pharma, Inc. | D' AMBROSIO, THEA | 1654 | §103 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18111070 | METHODS OF ANCHORING FRAGMENTED NUCLEIC ACID TARGETS IN A POLYMER MATRIX FOR IMAGING | Vizgen, Inc. | SCHLOOP, ALLISON ELIZABETH | 1683 | §103§112 | Final Rejection | 71d | Pending | Feb 17, 2023 |
| 18011261 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | Acceleron Pharma, Inc. | MIKNIS, ZACHARY J | 1658 | §112 | Non-Final OA | 21d | Pending | Dec 19, 2022 |
| 17602936 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTICS | Encoded Therapeutics, Inc. | REGLAS, GILLIAN CHELSEA | 1632 | §102§103§112 | Non-Final OA | 27d | Pending | Oct 11, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial